|本期目录/Table of Contents|

[1]刘娜娜 综 述,阚建英 审 校.局部枸橼酸抗凝用于重症患者血液净化的研究进展[J].天津医科大学学报,2019,25(01):90-93.
点击复制

局部枸橼酸抗凝用于重症患者血液净化的研究进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
25卷
期数:
2019年01期
页码:
90-93
栏目:
综述
出版日期:
2019-01-20

文章信息/Info

Title:
-
文章编号:
1006-8147(2019)01-0090-04
作者:
刘娜娜 综 述; 阚建英 审 校
（天津市中医药研究院附属医院ICU，天津300120）
Author(s):
-
关键词:
枸橼酸钠; ICU; 血液净化
Keywords:
-
分类号:
R459.5
DOI:
-
文献标志码:
A
摘要:
枸橼酸钠抗凝是目前对高危出血患者血液净化最常用的手段之一，枸橼酸钠在危重高出血风险患者行血液净化治疗抗凝中具有出血风险小、有效率和安全性高，避免了肝素诱导的血小板减少症引起的出血风险。
Abstract:
-

参考文献/References:


[1] 陈晓辉.血液净化在ICU的应用[M].北京:科学技术文献出版社，2012:119-119
[2] Hetzel G R，Schmitz M，Wissing H，et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial[J]. Nephrol Dial Transplant，2011，26(1):232
[3] Liao Y J，Zhang L，Zeng X X，et al. Citrate versus unfractionated heparin for anticoagulation in continuous renal replacement therapy[J]. Chin Med J (Engl)，2013，126(7):1344
[4] 杨德淑，杨平，张艳，等.不同抗凝方案在严重脓毒血症血小板减少患者CRRT中的应用[J]. 重庆医学，2014，43(28):3724
[5] Nurmohamed S A， Jallah B P， Vervloet M G， et al.Continuous venovenous haemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with a bleeding tendency:a prospective observational study[J]. BMC Nephrol，2013，14(1):89
[6] 赵筱娟，李红莉，安文军.血液透析过程中局部枸橼酸钠抗凝和普通肝素抗凝的临床随机对照研究[J].实用药物与临床，2018，21(3):279
[7] 赵海霞，于洋，崔天蕾，等.维持性血液透析患者采用不同抗凝剂封存Cuff导管的临床对照观察[J]. 肾脏病与透析肾移植杂志，2014，23(6):539
[8] 张颖萍，秦龙，刘秋旻.局部枸橼酸抗凝与全身肝素抗凝治疗脓毒症急性肾损伤的效果对比[J]. 临床研究，2017，431(4):470
[9] 王奎，杨定平.局部枸橼酸抗凝在高危出血风险血液透析患者中的应用[J]. 临床肾脏病杂志，2018，18(1):17
[10] 王昌芳，张斌.局部枸橼酸抗凝用于重症患者血液净化的研究进展[J].中国现代医药杂志，2016，18(9):95
[11] 贾利宁，桂保松.枸橼酸钠抗凝在血液净化中的应用进展[J]. 国际移植与血液净化杂志，2006，4(4):7
[12] Jacobs R， Honore P M， Bagshaw S M， et al. Citrate formulation determines filter lifespan during continuous Veno-Venous hemofiltration: a prospective cohort study[J]. Blood Purif,2015,40(3):194
[13] Schwarzer P, Kuhn S O, Stracke S, et al. Discrepant post filter ionized Calcium concentrations by common blood gas analyzers in CRRT using regional citrate anticoagulation[J]. Crit Care,2015,19(1):321
[14] Mariano F, Morselli M, Bergamo D, et al. Blood and ultrafiltrate dosage of citrate as a useful and routine tool during continuous venovenous haemodiafiltration in septic shock patients[J]. Nephrology Dialysis Transplantation,2011,26(12): 3882
[15] Fall P, Szerlip H M. Continuous renal repalcement therapy:cause and treatment of electrolyte complications[J]. Semin Dial,2010,23(6):581
[16] Hofbauer R, Moser D, Frass M, et al. Effect of anticoagulation on blood membr ane interactions during hemodialysis[J]. Kidney Int, 1999, 56(4):1578
[17] Dhondt A, Vanholder R, Tielemans C, et al. Effect of regional citrate anticoagul-ation on leucopenia,complement activation,and expression of leukocyte surface molecules during hemodialysis with unmodified cellulose membranes[J]. Nephron,2000,85(4):334
[18] Janssen M J, Huijgens P C, Bouman A A, et al. Citrate versus heparin anticoagula-tion in chronic haemodialysis patients[J].Nephrol Dial Transplant, 1993, 8(11):1228
[19] Gabutti L, Ferrari N, Mombelli G,et al. The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation[J]. J Nephrol,2004,17(6): 819
[20] Kutsogiannis D J, Mayers I, Chin W D, et al. Regional citrate anticoagulation in continuous venovenous hemodiafiltration[J]. Am J Kidny Dis, 2000, 35(5):802
[21] Claure-Del Granado R, Macedo E, Soroko S A, et al. Anticoagulation, delivered dose and outcomes in CRRT: The program to improve care in acute renal disease (PICARD)[J]. Hemodial Int, 2014, 18(3):641
[22] Straaten O V. Citrate for continuous renal replacement therapy:safer,better and cheaper[J]. Critical Care, 2014, 18(6):1
[23] Oudemans-Van Straaten H M, Bosman R J,Koopmans M, et al.Citrate anticoagulation for continuous venovenous hemofiltration[J]. Crit Care Med, 2009, 37(2):545
[24] 赖妙玉,朱德霞.枸橼酸-葡萄糖酸钙在高危出血患者连续血液净化中的应用[J]. 泰山医学院学报, 2017, 38(4):400
[25] Wu M Y, Hsu Y H, Bai C H, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials[J]. Am J Kidney Dis,2012, 59(6):810
[26] Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients[J].Crit Care Med, 2003, 31(10):2450
[27] Lahmer T, Messer M, Rasch S, et al. Sustained low-efficiency dialysis with regional citrate anticoagulation in medical intensive care unit patients with liver failure: A prospective study[J]. J Crit Care,2015, 30(5):1096
[28] Slowinski T, Morgera S, Joannidis M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovernous hemodialysis in the presence of liver failure: the liver citrate anticoagulation threshold(L-CAT) observational study[J]. Crit Care, 2015, 19:349
[29] Medow J E, Sanghvi S R, Hofmann R M. Use of High-Flow ContinuousRenal Replacement Therapy with Citrate Anticoagulationto Control ICP by Maintaining Hypernatremia in a Patient with Acute Brain Injury and Renal Failure[J]. Clin Med Res, 2014, 8:1238
[30] 李玲,倪春燕.脑干出血伴急性肾衰竭1例床旁血液净化枸橼酸抗凝治疗及临床护理[J]. 齐鲁护理杂志, 2016, 22(3):94
[31] Gille J, Sablotzki A, Malcharek M, et al. Regional citrate anticoagulation for continuous renal replacement therapy in severe burnsa retrospective analysis of a protocol-guided approach[J]. Burns, 2014, 40(8):1593
[32] Vico P D, Messino V, Tartaglione A, et al. Safety and efficacy of citrate anticoagulation continuous renal replacement therapies in postcardiac surgery patients with liver dysfunction[J]. Therapeutic Apheresis and Dialysis, 2015, 19(3):272
[33] Ponikvar R, Gubensek J, Ponikvar J B. Citrate anticoagulation in tandem membrane Plasma-Exchange or immunoadsorption and hemodialysis in patients with immunological diseases and Dialysis-Dependence[J]. Ther Apher Dial, 2016, 20(3, SI):246
[34] Shum H P, Ming-Chit K A, Chan K C, et al. The use of regional citrate anticoagulation continuous venovenous haemofiltration in extra-corporeal membrane oxygenation[J]. ASAIO J, 2014, 60(4):413
[35] Rico M P, Fernandez S J, Rojas V A, et al. Regional citrate anticoagulation for continusous renal replacement therapy in children[J]. Pediatr Nephrol, 2017, 32(4):703
[36] Chao L, Zhi M, Kang H, et al. Regional citrate versus heparin anticoagulation for continus renal replacement therapy in critically ill patients:a meta-analysis with trial sequential analysis of randomized controlled trials[J]. Critical Care, 2016, 20(1):1

相似文献/References:

[1]包佳婷,王勇强,王 兵,等.2014-2017年我院鲍曼不动杆菌分布及ICU内鲍曼不动杆菌耐药性分析[J].天津医科大学学报,2019,25(06):600.
　BAO Jia-ting,WANG Yong-qiang,WANG Bing,et al.Analysis on the distribution of Acinetobacter baumannii in our hospital and the drug resistance of Acinetobacter baumannii in ICU from 2014 to 2017[J].Journal of Tianjin Medical University,2019,25(01):600.

备注/Memo

备注/Memo:

作者简介 刘娜娜（1980-），女，主治医师，硕士，研究方向：重症医学；通信作者：阚建英，E-mail:kjy_123@yeah.net。
更新日期/Last Update: 2019-03-01